2月25日,康方生物自主研发的IL-4Rα单抗曼多奇单抗(AK120)注射液的上市申请(NDA)已获NMPA正式受理,适应症为中重度特应性皮炎(AD)。这是继赛诺菲/再生元的度普利尤单抗(Dupixent)、康诺亚的司普奇拜单抗(CM310)两款已上市药品,以及康乃德/先声药业的乐德奇拜单抗、智翔金泰的泰利奇拜单抗(GR1802)、MG-K10是麦济生物申报上市后,自免领域迎来的又一重磅新药,IL...
Source Link2月25日,康方生物自主研发的IL-4Rα单抗曼多奇单抗(AK120)注射液的上市申请(NDA)已获NMPA正式受理,适应症为中重度特应性皮炎(AD)。这是继赛诺菲/再生元的度普利尤单抗(Dupixent)、康诺亚的司普奇拜单抗(CM310)两款已上市药品,以及康乃德/先声药业的乐德奇拜单抗、智翔金泰的泰利奇拜单抗(GR1802)、MG-K10是麦济生物申报上市后,自免领域迎来的又一重磅新药,IL...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.